Literature DB >> 29266714

Touchscreen learning deficits in Ube3a, Ts65Dn and Mecp2 mouse models of neurodevelopmental disorders with intellectual disabilities.

P T Leach1, J N Crawley1.   

Abstract

Mutant mouse models of neurodevelopmental disorders with intellectual disabilities provide useful translational research tools, especially in cases where robust cognitive deficits are reproducibly detected. However, motor, sensory and/or health issues consequent to the mutation may introduce artifacts that preclude testing in some standard cognitive assays. Touchscreen learning and memory tasks in small operant chambers have the potential to circumvent these confounds. Here we use touchscreen visual discrimination learning to evaluate performance in the maternally derived Ube3a mouse model of Angelman syndrome, the Ts65Dn trisomy mouse model of Down syndrome, and the Mecp2Bird mouse model of Rett syndrome. Significant deficits in acquisition of a 2-choice visual discrimination task were detected in both Ube3a and Ts65Dn mice. Procedural control measures showed no genotype differences during pretraining phases or during acquisition. Mecp2 males did not survive long enough for touchscreen training, consistent with previous reports. Most Mecp2 females failed on pretraining criteria. Significant impairments on Morris water maze spatial learning were detected in both Ube3a and Ts65Dn, replicating previous findings. Abnormalities on rotarod in Ube3a, and on open field in Ts65Dn, replicating previous findings, may have contributed to the observed acquisition deficits and swim speed abnormalities during water maze performance. In contrast, these motor phenotypes do not appear to have affected touchscreen procedural abilities during pretraining or visual discrimination training. Our findings of slower touchscreen learning in 2 mouse models of neurodevelopmental disorders with intellectual disabilities indicate that operant tasks offer promising outcome measures for the preclinical discovery of effective pharmacological therapeutics.
© 2017 John Wiley & Sons Ltd and International Behavioural and Neural Genetics Society.

Entities:  

Keywords:  zzm321990Mecp2 Rett syndrome; zzm321990Ube3a; Angelman syndrome; Down syndrome; Ts65Dn; cognitive; intellectual disabilities; learning and memory; mice; neurodevelopmental disorders; touchscreen; water maze

Mesh:

Substances:

Year:  2018        PMID: 29266714      PMCID: PMC6013336          DOI: 10.1111/gbb.12452

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  78 in total

1.  Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn.

Authors:  Laura G Reinholdt; Yueming Ding; Griffith J Gilbert; Griffith T Gilbert; Anne Czechanski; Jeffrey P Solzak; Randall J Roper; Mark T Johnson; Leah Rae Donahue; Cathleen Lutz; Muriel T Davisson
Journal:  Mamm Genome       Date:  2011-09-28       Impact factor: 2.957

2.  Dissociation of locomotor and cerebellar deficits in a murine Angelman syndrome model.

Authors:  Caroline F Bruinsma; Martijn Schonewille; Zhenyu Gao; Eleonora M A Aronica; Matthew C Judson; Benjamin D Philpot; Freek E Hoebeek; Geeske M van Woerden; Chris I De Zeeuw; Ype Elgersma
Journal:  J Clin Invest       Date:  2015-10-20       Impact factor: 14.808

3.  A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome.

Authors:  J Guy; B Hendrich; M Holmes; J E Martin; A Bird
Journal:  Nat Genet       Date:  2001-03       Impact factor: 38.330

4.  Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists.

Authors:  Alexander M Kleschevnikov; Pavel V Belichenko; Mehrdad Faizi; Lucia F Jacobs; Khin Htun; Mehrdad Shamloo; William C Mobley
Journal:  J Neurosci       Date:  2012-07-04       Impact factor: 6.167

5.  Ampakines promote spine actin polymerization, long-term potentiation, and learning in a mouse model of Angelman syndrome.

Authors:  Michel Baudry; Eniko Kramar; Xiaobo Xu; Homera Zadran; Stephanie Moreno; Gary Lynch; Christine Gall; Xiaoning Bi
Journal:  Neurobiol Dis       Date:  2012-04-16       Impact factor: 5.996

6.  Behavioral assessment of the Ts65Dn mouse, a model for Down syndrome: altered behavior in the elevated plus maze and open field.

Authors:  M E Coussons-Read; L S Crnic
Journal:  Behav Genet       Date:  1996-01       Impact factor: 2.805

7.  Behavioral validation of the Ts65Dn mouse model for Down syndrome of a genetic background free of the retinal degeneration mutation Pde6b(rd1).

Authors:  Alberto C S Costa; Melissa R Stasko; Cecilia Schmidt; Muriel T Davisson
Journal:  Behav Brain Res       Date:  2009-08-29       Impact factor: 3.332

Review 8.  Preclinical research in Rett syndrome: setting the foundation for translational success.

Authors:  David M Katz; Joanne E Berger-Sweeney; James H Eubanks; Monica J Justice; Jeffrey L Neul; Lucas Pozzo-Miller; Mary E Blue; Diana Christian; Jacqueline N Crawley; Maurizio Giustetto; Jacky Guy; C James Howell; Miriam Kron; Sacha B Nelson; Rodney C Samaco; Laura R Schaevitz; Coryse St Hillaire-Clarke; Juan L Young; Huda Y Zoghbi; Laura A Mamounas
Journal:  Dis Model Mech       Date:  2012-11       Impact factor: 5.758

9.  The BTBR mouse model of autism spectrum disorders has learning and attentional impairments and alterations in acetylcholine and kynurenic acid in prefrontal cortex.

Authors:  Stephanie M McTighe; Sarah J Neal; Qian Lin; Zoë A Hughes; Daniel G Smith
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

10.  An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome.

Authors:  Pavel V Belichenko; Rime Madani; Lorianne Rey-Bellet; Maria Pihlgren; Ann Becker; Adeline Plassard; Stephanie Vuillermot; Valérie Giriens; Rachel L Nosheny; Alexander M Kleschevnikov; Janice S Valletta; Sara K S Bengtsson; Gordon R Linke; Michael T Maloney; David T Hickman; Pedro Reis; Anne Granet; Dorin Mlaki; Maria Pilar Lopez-Deber; Long Do; Nishant Singhal; Eliezer Masliah; Matthew L Pearn; Andrea Pfeifer; Andreas Muhs; William C Mobley
Journal:  PLoS One       Date:  2016-03-29       Impact factor: 3.240

View more
  7 in total

1.  Behavioral Evaluation of Angelman Syndrome Mice at Older Ages.

Authors:  Rebecca Dutta; Jacqueline N Crawley
Journal:  Neuroscience       Date:  2019-11-12       Impact factor: 3.590

2.  Extended Erythropoietin Treatment Prevents Chronic Executive Functional and Microstructural Deficits Following Early Severe Traumatic Brain Injury in Rats.

Authors:  Shenandoah Robinson; Jesse L Winer; Lindsay A S Chan; Akosua Y Oppong; Tracylyn R Yellowhair; Jessie R Maxwell; Nicholas Andrews; Yirong Yang; Laurel O Sillerud; William P Meehan; Rebekah Mannix; Jonathan L Brigman; Lauren L Jantzie
Journal:  Front Neurol       Date:  2018-06-19       Impact factor: 4.003

Review 3.  Construction and disruption of spatial memory networks during development.

Authors:  Tallie Z Baram; Flavio Donato; Gregory L Holmes
Journal:  Learn Mem       Date:  2019-06-17       Impact factor: 2.460

4.  Hypothesis-driven investigations of diverse pharmacological targets in two mouse models of autism.

Authors:  Maya A Rhine; Jennifer M Parrott; Maria N Schultz; Tatiana M Kazdoba; Jacqueline N Crawley
Journal:  Autism Res       Date:  2019-01-17       Impact factor: 5.216

5.  Deficits in higher visual area representations in a mouse model of Angelman syndrome.

Authors:  Leah B Townsend; Kelly A Jones; Christopher R Dorsett; Benjamin D Philpot; Spencer L Smith
Journal:  J Neurodev Disord       Date:  2020-10-19       Impact factor: 4.025

6.  Touchscreen cognitive deficits, hyperexcitability and hyperactivity in males and females using two models of Cdkl5 deficiency.

Authors:  Anna Adhikari; Fiona K B Buchanan; Timothy A Fenton; David L Cameron; Julian A N M Halmai; Nycole A Copping; Kyle D Fink; Jill L Silverman
Journal:  Hum Mol Genet       Date:  2022-09-10       Impact factor: 5.121

7.  Translational outcomes in a full gene deletion of ubiquitin protein ligase E3A rat model of Angelman syndrome.

Authors:  E L Berg; M C Pride; S P Petkova; R D Lee; N A Copping; Y Shen; A Adhikari; T A Fenton; L R Pedersen; L S Noakes; B J Nieman; J P Lerch; S Harris; H A Born; M M Peters; P Deng; D L Cameron; K D Fink; U Beitnere; H O'Geen; A E Anderson; S V Dindot; K R Nash; E J Weeber; M Wöhr; J Ellegood; D J Segal; J L Silverman
Journal:  Transl Psychiatry       Date:  2020-01-27       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.